USPTO serial 79444386
MYRICX
Reviewed by CopyMark Law Group
Status 681
- Filing date
- Status date
- Registration date
- —
- Examiner
- SUK, HAE P
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with MYRICX?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Andrea L Calvaruso
Andrea L Calvaruso Kelley, Drye & Warren LLP175 Greenwich StreetThree World Trade CenterNew York, NY 10007Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical and biotechnological preparations for human diseases, namely, cancer, fibrosis, inflammation, senescence, and diseases of aging; pharmaceutical and biotechnological preparations for the diagnosis and treatment of human diseases, namely, cancer, fibrosis, inflammation, senescence, and diseases of aging; pharmaceutical and biotechnological preparations for the diagnosis and treatment of proliferative human diseases, namely, cancer, fibrosis, inflammation, senescence, and diseases of aging; pharmaceutical and biotechnological preparations for the diagnosis and treatment of diseases, namely, cancer, fibrosis, inflammation, senescence and diseases of aging; antibody drug conjugates (ADCs) for medical purposes; antibody drug conjugates (ADCs) for medical purposes for the diagnosis and treatment of human diseases; antibody drug conjugates (ADCs) for medical purposes for the diagnosis and treatment of proliferative human diseases; antibody drug conjugates (ADCs) for medical purposes for the diagnosis and treatment of diseases including cancer, fibrosis, inflammation, senescence and diseases of aging; N-myristoyltransferases (NMT) inhibitors in the nature of enzymes for medical purposes; N-myristoyltransferases (NMT) inhibitors in the nature of enzymes for medical purposes for the diagnosis and treatment of human diseases; Nmyristoyltransferases (NMT) inhibitors in the nature of enzymes for medical purposes for the diagnosis and treatment of proliferative human diseases; N-myristoyltransferases (NMT) inhibitors in the nature of enzymes for medical purposes for the diagnosis and treatment of diseases including cancer, fibrosis, inflammation, senescence and diseases of aging | ACTIVE | — |
| 035 | New product commercialisation services of pharmaceuticals and biotechnological preparations; new product commercialisation services of pharmaceuticals and biotechnological preparations for the diagnosis and treatment of human diseases; new product commercialisation services of pharmaceuticals and biotechnological preparations for the diagnosis and treatment of proliferative human diseases; new product commercialisation services of pharmaceuticals and biotechnological preparations for the diagnosis and treatment of diseases including cancer, fibrosis, inflammation, senescence and diseases of aging; new product commercialisation services of antibody drug conjugates (ADCs) and N-myristoyltransferases (NMT) inhibitors; consultancy, advisory and information services relating to the aforesaid services | ACTIVE | — |
| 042 | Scientific and biomedical research; scientific and biomedical research in the field of human diseases; scientific and biomedical research in the field of proliferative human diseases; scientific and biomedical research in the field of diseases including cancer, fibrosis, inflammation, senescence and diseases of aging; development and testing of pharmaceuticals and biotechnological preparations; scientific and technological research, development and testing of pharmaceuticals and biotechnological preparations, and scientific and technological research for their commercialisation; development and testing of pharmaceuticals and biotechnological preparations for the diagnosis and treatment of human diseases; development and testing of pharmaceuticals and biotechnological preparations for the diagnosis and treatment of human diseases, and scientific and technological research supporting their commercialisation; development and testing of pharmaceuticals and biotechnological preparations for the diagnosis and treatment of proliferative human diseases; development and testing of pharmaceuticals and biotechnological preparations for the diagnosis and treatment of proliferative human diseases, and scientific and technological research supporting their commercialisation; development and testing of pharmaceuticals and biotechnological preparations for the diagnosis and treatment of diseases including cancer, fibrosis, inflammation, senescence and diseases of aging; development and testing of pharmaceuticals and biotechnological preparations for the diagnosis and treatment of diseases including cancer, fibrosis, inflammation, senescence, and diseases of aging, and scientific and technological research supporting their commercialisation; pharmaceutical product development and testing of antibody drug conjugates (ADCs) and Nmyristoyltransferases (NMT) inhibitors; pharmaceutical product development and testing of antibody-drug conjugates (ADCs) and N-myristoyltransferase (NMT) inhibitors, and scientific and technological research supporting their commercialisation; consultancy, advisory and information services relating to the aforesaid services | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 7, 2026 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Oct 7, 2026 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Sep 24, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 24, 2026 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Sep 24, 2026 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Sep 24, 2026 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Sep 24, 2026 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Sep 21, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 21, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 21, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 23, 2026 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jul 4, 2026 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jul 4, 2026 | RFRR | REFUSAL PROCESSED BY MPU | — |
| May 14, 2026 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| May 13, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 3, 2026 | RFWR | NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW | — |
| May 1, 2026 | CREV | CORRECTION FROM IB ENTERED - ATTORNEY REVIEW REQUIRED | — |
| Mar 26, 2026 | CRCV | CORRECTION TRANSACTION RECEIVED FROM IB | — |
| Mar 4, 2026 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Mar 3, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 28, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 27, 2026 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Feb 27, 2026 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Feb 26, 2026 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |